Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07267299
PHASE4

Switching From Restasis to TRYPTYR

Sponsor: Southern College of Optometry

View on ClinicalTrials.gov

Summary

Switching to acoltremon 0.003% will significantly improve the signs and symptoms of participants who were being treated with Restasis at 28 days post-treatment compared to baseline. Dry eye disease (DED) is a prevalent condition that commonly affects patients of working age in addition to the elderly. DED is a complex condition that results in ocular symptoms such as dryness and burning and signs such as decreased tear production (aqueous deficient DED) or increased tear evaporation (evaporative DED). Unfortunately, there is not a perfect correlation between DED signs and symptoms, which makes diagnosis and timely treatment challenging.

Official title: Efficacy of Switching Participants Treated With Restasis to TRYPTYR

Key Details

Gender

All

Age Range

18 Years - 100 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2025-12-01

Completion Date

2026-05-15

Last Updated

2025-12-05

Healthy Volunteers

No

Interventions

DRUG

acoltremon 0.003%

Participants who are using restasis will be switched to acoltremon 0.003%